Why Scale Is Suddenly Everything in Rare Disease Drugs

BioMarin’s Amicus deal highlights a pivot toward scale, steady revenue, and broader portfolios as rare disease companies brace for more mergers

3 Feb 2026

A new phase is taking shape in the US rare disease drug market, and it favors size, staying power, and products that already pay the bills. BioMarin’s agreement to buy Amicus stands out not just for its price tag, but for what it signals about where the sector is headed.

For years, many rare disease companies succeeded with a single therapy aimed at a tightly defined patient group. Regulatory incentives were generous, competition was thin, and investors rewarded focus. That playbook is now under strain. More drugs have reached approval, insurers are asking tougher questions, and capital has grown harder to secure. In response, companies are looking for depth, durability, and revenue they can count on.

The BioMarin Amicus deal fits squarely into that shift. Amicus brings two approved treatments for rare genetic disorders that together generated about $599 million in net product revenue over the past four quarters. That kind of steady income helps cushion the risk of experimental programs still moving through clinical trials. Analysts say it also shows that commercial stage assets are now prized more highly than early science alone.

There is a strategic logic on both sides. BioMarin adds predictable cash flow and a broader patient footprint. Amicus gains scale, along with a global commercial and manufacturing platform that would have been expensive and slow to build on its own. Its pipeline, including the Phase 3 candidate DMX-200, also stays alive within a larger balance sheet.

The ripple effects are already visible. Industry analysts point to mounting pressure on mid-sized rare disease specialists to bulk up, merge, or partner. As markets mature, companies with several approved drugs are better positioned to handle regulators, negotiate with insurers, and ensure reliable supply. Rivals such as Vertex are widely seen as watching closely.

Consolidation carries risks. Integrating teams can be messy, and fewer independent players may narrow the range of ideas. Supporters argue that larger, better-funded groups are often best equipped to carry costly trials to the finish line.

Even so, momentum appears to be building. More deals centered on approved or near-market therapies are expected as companies hunt for stable growth. The message is becoming hard to miss. In rare disease drugmaking, scale is no longer optional.